All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
In January 2016 Meletios Dimopoulos and Philippe Moreau published the findings from the ENDEAVOR phase III trial, to compare the efficacy of the proteasome inhibitor (PI) carfilzomib administered in combination with dexamethasone, with the standard regimen of bortezomib and dexamethasone, to treat patients with relapsed and refractory Multiple Myeloma (RRMM). This study was published in The Lancet Oncology, and built upon previously published phase Ib/II and phase II studies, which showed early promise for carfilzomib in comparison to bortezomib. This open-label, multi-center study included 929 patients with RRMM, recruited from 198 sites globally between June 2012 and June 2014, who had one to three previous treatments. Patients were randomly assigned to either the carfilzomib (464) or bortezomib (465) group. The primary endpoint was progression free survival (PFS); secondary endpoints included overall survival (OS) and overall response (OR).
This was the first phase III trial to compare two protease inhibitors head-to-head, and provided comparative efficacy data for carfilzomib and bortezomib treatment regimens. Carfilzomib was found to confer a longer PFS, when compared with bortezomib, as well as more durable responses. Therefore, the authors concluded that carfilzomib, in combination with dexamethasone, should be considered a valid treatment option for patients for which bortezomib and dexamethasone would have been considered. The results from this trial provided pivotal data leading to the approval of a carfilzomib plus dexamethasone combination, for the treatment of RRMM patients, by both the US FDA and the EMA.
References
Your opinion matters
Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?